Q-omics provides the consensus-scored MIR7849 profile across patient tissues and cancer cell-line models. MIR7849 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MIR7849 is differentially expressed in 2, with the highest sampling consensus in LIHC. Additionally, MIR7849 RNA expression shows 5,273 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, LIHC, and THYM as cancer lineages where MIR7849 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR7849 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR7849 survival associations across molecular data types. MIR7849 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR7849 RNA expression–survival associations across cancer types. High MIR7849 expression shows unfavorable associations in UVM, COAD, THCA, MESO and UCEC, but favorable associations in OV. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MIR7849 RNA expression.
This table summarizes MIR7849 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR7849. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR7849 shows lower tumor expression in LUAD and higher tumor expression in LIHC. The LIHC box plot shows higher MIR7849 RNA expression in tumor versus normal tissue (log2 FC = +0.297, t-test p = .017).
This table shows molecular features associated with MIR7849 in patient tissues and cancer cell lines. In patient samples, MIR7849 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
